Menu Search
Equities

Mega Genomics Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
6667:HKG.HS

Mega Genomics Ltd

Actions
  • Price (HKD)7.20
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change-12.52%
  • Beta0.6757
Data delayed at least 15 minutes, as of Feb 13 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Mega Genomics Ltd is an investment holding company primarily engaged in the provision of genetic testing and cancer screening services. The Company operates through Namely Consumer Genetic Testing Services segment and Cancer Screening Services segment. The Company's testing services include Brain Health Assessment Package, Alimentation Capability Assessment Package, Parkinson's Disease Risk Assessment, Full-scale Cancer Risk Assessment Package, Cardiovascular and Cerebrovascular Disease Risk Assessment Package and others. The Company is also engaged in the provision of vitro diagnostics (IVD) pipeline products, including consumer genetic testing products and disease screening products. The Company primarily conducts its businesses in domestic market.

  • Revenue in HKD (TTM)156.37m
  • Net income in HKD39.98m
  • Incorporated2021
  • Employees203.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.